PsilodexMedication × psilocybin
Your list , 0 items
Medication class

GLP-1 and weight-loss medications and psilocybin.

14 records in this group. None has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

14Records
0With human data

Also searched as GLP-1 · GLP1 · weight-loss shot · weight loss shot · weight-loss injection · skinny shot

01 What the evidence covers

Best evidence available per medication
14No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Cagrilintide–semaglutide · CagriSemaEvidence: No psilocybin data

    Peptides

    Both parts slow stomach emptying, which may delay psilocybin absorption and add to nausea. Also, semaglutide's stomach side effects can lead to dehydration.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Dulaglutide · TrulicityEvidence: No psilocybin data

    Type 2 diabetes (with diet and exercise); Lowering risk of heart attack, stroke, and cardiovascular death in type 2 diabetes

    Its nausea may add to psilocybin's, and it may delay psilocybin's onset (untested). Also, with insulin or a sulfonylurea, blood sugar can drop too low.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Exenatide · Byetta, Bydureon BCiseEvidence: No psilocybin data

    Type 2 diabetes (with diet and exercise)

    Its nausea may add to psilocybin's nausea. Also, with insulin or a sulfonylurea, blood sugar can drop too low.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Insulin degludec–liraglutide · Xultophy 100/3.6Evidence: No psilocybin data

    Type 2 diabetes (with diet and exercise)

    It may slow psilocybin absorption and add nausea, and its insulin can lower blood sugar. Stopping or pausing it can raise blood sugar.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Insulin glargine–lixisenatide · SoliquaEvidence: No psilocybin data

    Type 2 diabetes (with diet and exercise)

    It may slow psilocybin absorption and add nausea, and its insulin can lower blood sugar. Stopping or pausing it can raise blood sugar.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Liraglutide · Victoza, SaxendaEvidence: No psilocybin data

    Type 2 diabetes (with diet and exercise); Reducing heart attack, stroke and cardiovascular death risk in type 2 diabetes with heart disease

    Its nausea may add to psilocybin's, and its effect on psilocybin absorption is unknown. Also, blood sugar can drop when used with insulin or sulfonylureas.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Naltrexone–bupropion · ContraveEvidence: No psilocybin data

    Weight management in adults with obesity, or overweight with a weight-related condition (with diet and exercise)

    Not studied with psilocybin; its label warns of psychosis, mania and suicidal thinking, so overlap with psilocybin's effects is possible. Also, it lowers seizure threshold.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Orforglipron · FoundayoEvidence: No psilocybin data

    Chronic weight management (obesity, or overweight with a weight-related condition)

    It slows stomach emptying, which may delay or reduce psilocybin absorption and add nausea.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Orlistat · Alli, XenicalEvidence: No psilocybin data

    Weight loss in overweight adults (over-the-counter, with reduced-calorie, low-fat diet); Obesity management, weight maintenance and reducing weight regain (prescription)

    Not studied with psilocybin; it causes oily, urgent stools, so added stomach upset is possible. Also, it is a probable rare cause of liver injury.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Phentermine · AdipexEvidence: No psilocybin data

    Obesity (short-term, with diet, exercise and behavior change)

    Not studied with psilocybin; it raises blood pressure and heart rate, so an added rise is possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Phentermine–topiramate · QsymiaEvidence: No psilocybin data

    Weight management in obesity (adults and ages 12+) or adult overweight with a weight-related condition (with diet and exercise)

    Phentermine's rise in blood pressure and heart rate may add to psilocybin's. Stopping it suddenly after regular use can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • RetatrutideEvidence: No psilocybin data

    Peptides

    It slows stomach emptying, which may delay psilocybin absorption and add nausea, and it raises heart rate. Also, outside a trial, product content is unverified.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Semaglutide · Ozempic, WegovyEvidence: No psilocybin data

    Type 2 diabetes (with diet and exercise); Lowering heart attack, stroke and cardiovascular death risk in type 2 diabetes

    Its nausea can add to psilocybin's, and it may delay absorption of oral psilocybin. Also, blood sugar can drop with insulin or sulfonylureas.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tirzepatide · Mounjaro, ZepboundEvidence: No psilocybin data

    Type 2 diabetes (with diet and exercise); Lowering risk of major cardiovascular events in type 2 diabetes

    It may delay absorption of oral psilocybin (not studied), and its nausea can add to psilocybin's. Also, blood sugar can drop with insulin or sulfonylureas.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
10Slows gastric emptying
8Dehydration or electrolyte risk
8Hypoglycemia risk
7Raises blood pressure or heart rate
4Withdrawal or rebound if stopped abruptly
3Psychiatric reactions
1Liver injury
1Lowers seizure threshold or carries seizure risk
1Opioid blocker
1Sedating or CNS depressant
1Speeds up drug metabolism

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 2 of the 14 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
5Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
5Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
2Singhani V, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: a narrative expert review. Nutr Clin Pract 2026;41(5):1318–1333.
1Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022;34(9):1234–1247.
1Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389(6):514–526.
1Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689.

Related classes

Records reviewed 2026-10-03 to 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25